Selenium Ltd. And Pinpoint Med Inc. To Develop Interventional Catheter Device

Emergent Technologies Inc. (ETI) of Austin announced today that one of its Lubbock-based biotechs, Selenium Ltd., has agreed with Pinpoint Med Inc (PMI), Glil Yam, Israel, to develop an interventional catheter device which employs Selenium's patented technology.

Dr. Ascher Shmulewitz of PMI commented, "Pinpoint Med Inc (PMI) is excited about the potential solution to one of the last frontiers in interventional cardiology. The PMI interventional catheter device allows the controlled delivery of the potent biological effects of the Selenium technology. The convergence of these two technologies may provide a cost effective and safe solution to the debulking of chronic total occlusions of blood vessels - a condition that, at present, requires in most patients bypass surgery."

Dr. Brian Windsor, ETI Vice President, stated, "The Selenium technology was developed by Drs. Ted Reid and Julian Spallholz at Texas Tech University Health Sciences Center in Lubbock, Texas. One application of the technology addresses an industry need for development of device coatings which are more reliable, non-toxic, non-leaching, and suitable for controlled local delivery by using catalytic production of locally toxic super-oxide radicals to inhibit bacteria, viruses, cellular and biofilm growth and formation. The coating technology will be homogeneously applied to achieve predictable and reproducible high quality results for PMI's catheter devices."